Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy

Anis, A.H.; Hogg, R.S.; Wang, X-h.; Yip, B.; Palepu, A.; Montaner, J.S.G.; O’Shaughnessy, M.V.; Schechter, M.T.; Montaner, J S; O'Shaughnessy, M V
June 1998
PharmacoEconomics;1998, Vol. 13 Issue 6, p697
Academic Journal
journal article
The purpose of this study is to model the potential economic impact of viral load-driven triple drug combination (including a protease inhibitor) antiretroviral therapy on incremental drug and hospitalisation costs among individuals with HIV disease. Individuals included in the study were HIV-positive men and women from the province of British Columbia, Canada, who were aged 18 years or older and had given consent to access their medical records. The study employed pharmacoeconomic modelling of drug- and hospital-utilisation patterns among a population-based cohort with free access to antiretroviral therapy. Protease inhibitor use and associated costs based on actual use in a subsequent period was modelled upon men and women who were able to maintain stable CD4+ cell counts (slope ≥ 0) for at least 6 months (baseline period) with an average follow-up period of 30 months (protease-like group). A control was modelled upon individuals with declining CD4+ cell counts (slope < 0) during similar baseline and follow-up periods. The primary outcome measure was average annual incremental cost of triple drug therapy net of hospitalisation and testing costs in 1996 Canadian dollars ($Can). The utilisation pattern of drugs and hospitals was modelled from actual use among a total of 1271 individuals who were eligible for this analysis. Programme participants who gave consent to access their medical records were more likely to be men (p < 0.001), older (p < 0.020), and on antiretroviral therapy (p < 0.001) than programme participants who did not give consent. No differences were observed between the protease-like and comparison groups with respect to age (p = 0.65) and CD4+ cell count (p = 0.30) at study entry. Over a period of 1 year, the protease-like group was shown to spend less time in hospital (2.7 vs 6.6 days; p < 0.001). This difference in hospitalisation remained in multivariate models, adjusting for prior AIDS-defining illnesses and gender. The average annual incremental cost of adding a protease inhibitor to a 2-drug antiretroviral regimen was estimated to be $Can2318 per person. The cost implications of hospital stay while using a protease inhibitor drug and 2 nucleosides translated into an average annual incremental cost (savings if negative) of between -$Can4798 and - $Can2227 per person. The overall average annual incremental cost impact per person associated with triple drug therapy with a protease inhibitor varied between -$Can2288 to $Can283. Negative incremental costs imply overall savings from adopting triple combination therapy. This modelling exercise demonstrated that the cost of triple drug combination antiretroviral therapy with a protease inhibitor among HIV-positive men and women was considerably less than the expected acquisition cost of the drug alone due to hospitalisation savings in the province of British Columbia.


Related Articles

  • Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, Lopinavir-Naive, Protease Inhibitor- Resistant, HIV-Infected Adults in Belgium, Italy, Sweden and the UK. Moeremans, Karen; Hemmett, Lindsay; Hjelmgren, Jonas; Allegri, Gabriele; Smets, Erik // PharmacoEconomics;2010 Supplement, Vol. 28, p147 

    Background: Using data from the phase IIb POWER trials, darunavir boosted with low-dose ritonavir (DRV/r; 600/100mg twice daily; bid)-based highly active antiretroviral therapy (HAART) was shown to be significantly more efficacious and cost effective than other protease inhibitor (PI)-based...

  • Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. Hubben, Gijs A. A.; Bos, Jasper M.; Veltman-Starkenburg, Christa A.; Stegmeijer, Simon; Finnern, Henrik W.; Kappelhoff, Bregt S.; Simpson, Kit N.; Tramarin, Andrea; Postma, Maarten J. // Cost Effectiveness & Resource Allocation;2007, Vol. 5, p15 

    Background: This study compares the costs and effects of a regimen with ritonavir-boosted tipranavir (TPV/r) to a physician-selected genotypically-defined standard-of-care comparator protease inhibitor regimen boosted with ritonavir (CPI/r) in HIV infected patients that were previously exposed...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Aug2001, Vol. 15 Issue 8, p443 

    Presents updates on antiviral drugs compiled as of August 2001. Effect of two active ingredients in milk thistle on liver enzymes; Effects of protease inhibitors on weight and other growth parameters in children and adolescents with HIV infection; Use of genotypic resistance testing in the...

  • Combination Treatment for HIV.  // Combination Treatment for HIV;4/1/2004, p1 

    The article presents information about combination treatment for human immunodeficiency viruses (HIV). It enumerates the four main types of HIV drugs namely nucleoside analogues, non-nucleoside analogues, protease inhibitors and fusion inhibitors. It cites the side effects of combining these...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Oct2000, Vol. 14 Issue 10, p567 

    Presents various medical news briefs related to side effects of antiviral drugs for HIV infections. Ability of protease inhibitors to cause sexual dysfunction; Role of highly active antiretroviral therapy in causing curly hair; Interaction between Viagra and ritonavir or saquinavir.

  • EFAVIRENZ POTENT IN ADULTS.  // AIDS Patient Care & STDs;Mar2000, Vol. 14 Issue 3, p170 

    Cites the findings of a DuPont 006 study regarding the use of efavirenz when compared to the protease inhibitor indinavir. Support for the use of efavirenz among HIV patients who are treatment-naive; Random assignments into possible treatment regimens.

  • WARNING FOR LOPINAVIR/RITONAVIR ORAL SOLUTION.  // Contemporary Pediatrics;Apr2011, Vol. 28 Issue 4, p16 

    The article reports a warning issued by the US Food and Drug Administration (FDA), as it has estimated severe, possibly fatal, health problems in babies who have received lopinavir/ritonavir oral solution, an antiviral medication used in combination with other antiretroviral drugs to treat HIV-1...

  • The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS. Anis, A.H.; Guh, D.; Hogg, R.S.; Wang, X-H.; Yip, B.; Craib, K.J.P.; O'Shaughnessy, M.V.; Schechter, M.T.; Montaner, J.S.G.; Craib, K J; Montaner, J S // PharmacoEconomics;2000, Vol. 18 Issue 4, p393 

    Objective: To estimate survival, the number of life-years gained and cost effectiveness of antiretroviral therapy (ART) regimens, denoted as ERA-I [zidovudine + (didanosine or zalcitabine)]; ERA-II [stavudine + (didanosine or zalcitabine) or lamivudine + (zidovudine or didanosine or...

  • Building African AIDS Care from the Ground Up.  // Annals of Internal Medicine;7/15/2003, Vol. 139 Issue 2, p157 

    The epicenter of AIDS activity in the early 1980s was San Francisco General Hospital, where Merle Sande, MD, was chief of medicine. Within the next decade, physicians in the United States learned how to treat HIV infection and AIDS as pharmaceutical companies launched drugs that controlled the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics